Pharmacokinetics of HD-P023 vs. Co-administered Teneligliptin and Empagliflozin

Phase 1, randomised, open-label trial of teneligliptin + empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Handok. Primary endpoints: Area under the plasma concentration versus time curve from time 0 to the last measurable time point of Teneligliptin at 72 hours, Area under the plasma concentration versus time curve from time 0 to the last measurable time point of Empagliflozin at 72 hours and 2 more. Started Sep 2025; status: completed.